Abstract
MiRNAs are small noncoding RNA molecules that are often aberrantly over- or underexpressed in tumors, including colorectal cancer (CRC). Due to their capacity to regulate and thus fine-tune the expression of multiple target genes relevant in tumorigenesis, tumor progression, angiogenesis, metastasis and sensitivity towards chemotherapy, they influence various pivotal cellular processes with prognostic and therapeutic relevance in CRC.
This review provides a comprehensive overview of miRNAs with established functional relevance in colorectal cancer, their established target genes and the resulting cellular and pathological phenotype(s). Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs, and multiple strategies for the inhibition of oncogenic miRNAs. Beyond the analysis of the functional relevance of a given miRNA as target molecule or a miRNA-based drug, several studies in preclinical in vivo models are described that provide the basis for possible future therapeutic intervention in man.
Keywords: MiRNAs, colorectal cancer, anticancer therapy, novel miRNA-based therapies, miRNA replacement, antimiRs, nanoparticles, RNA delivery, phenotype, target molecule
Current Pharmaceutical Design
Title:MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Volume: 19 Issue: 7
Author(s): Hannelore Dassow and Achim Aigner
Affiliation:
Keywords: MiRNAs, colorectal cancer, anticancer therapy, novel miRNA-based therapies, miRNA replacement, antimiRs, nanoparticles, RNA delivery, phenotype, target molecule
Abstract: MiRNAs are small noncoding RNA molecules that are often aberrantly over- or underexpressed in tumors, including colorectal cancer (CRC). Due to their capacity to regulate and thus fine-tune the expression of multiple target genes relevant in tumorigenesis, tumor progression, angiogenesis, metastasis and sensitivity towards chemotherapy, they influence various pivotal cellular processes with prognostic and therapeutic relevance in CRC.
This review provides a comprehensive overview of miRNAs with established functional relevance in colorectal cancer, their established target genes and the resulting cellular and pathological phenotype(s). Furthermore, approaches towards therapeutic miRNA-based intervention are discussed. Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs, and multiple strategies for the inhibition of oncogenic miRNAs. Beyond the analysis of the functional relevance of a given miRNA as target molecule or a miRNA-based drug, several studies in preclinical in vivo models are described that provide the basis for possible future therapeutic intervention in man.
Export Options
About this article
Cite this article as:
Dassow Hannelore and Aigner Achim, MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy, Current Pharmaceutical Design 2013; 19 (7) . https://dx.doi.org/10.2174/138161213804805739
DOI https://dx.doi.org/10.2174/138161213804805739 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Docking Studies for Multi-Target Drugs
Current Drug Targets A Potent Anti-Carcinoma and Anti-Acute Myeloblastic Leukemia Agent, AG490
Anti-Cancer Agents in Medicinal Chemistry Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Nutrition in Allogeneic Stem Cell Transplantion - Clinical Guidelines and Immunobiological Aspects
Current Pharmaceutical Biotechnology Glycomics: Towards Bioinformatic Approaches to Understanding Glycosylation
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Protein and Cell-Targeted Aptamer Selection and Applications
Current Medicinal Chemistry Editorial
Recent Patents on Inflammation & Allergy Drug Discovery The Anticancer Role of Omega-3 Polyunsaturated Fatty Acids was Closely Associated with the Increase in Genomic DNA Hydroxymethylation
Anti-Cancer Agents in Medicinal Chemistry BTX AgilePulse<sup>TM</sup> System is an Effective Electroporation Device for Intramuscular and Intradermal Delivery of DNA Vaccine
Current Gene Therapy Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry